Front. Immunol.Frontiers in ImmunologyFront. Immunol.1664-3224Frontiers Media S.A.10.3389/fimmu.2022.1027539ImmunologyOpinionPublic awareness should be raised on a crucial but neglected factor for COVID-19 vaccinationYuanHao1SongYining1ZhangXiu-Xiang1ZhaiJingbo23ZhangJin4YuanZi-Guo1*1Guangdong Provincial Key Laboratory of Zoonosis Prevention and Control, College of Veterinary Medicine, South China Agricultural University, Guangzhou, China2Medical College, Inner Mongolia Minzu University, Tongliao, China3Key Laboratory of Zoonose Prevention and Control at Universities of Inner Mongolia Autonomous Region, Tongliao, China4Department of Pharmacy and Toxicology, University of Missippi Medical Center, Jackson, MS, United States
Edited by: Chenhe Su, Wistar Institute, United States
Reviewed by: Yuexiu Zhang, The Ohio State University, United States; Biao Qiu, NewYork-Presbyterian, United States
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
According to the current epidemic trend, herd immunity can be achieved via a vaccination program on a wide scale, representing one of the important ways to block the spread of COVID-19 (Corona Virus Disease 2019). Herd immunity is largely affected by the frequency of vaccination and the type of vaccine. Currently, the low vaccine protection rate is mostly attributed to a) there is no vaccine for children under 6 months, and exemption of partial population with neurologic disorder and anaphylactic disease and immunocompromised patients from receiving the vaccine, and b) the emergence of variant strains across the world has greatly reduced the protection of the vaccine. In addition, a significant factor may be neglected: the influence of immunosuppressive parasite infection.
As of August 2022. 343.0624 million COVID-19 vaccines have been vaccinated across China (1). Due to the differences in the coverage of COVID-19 vaccines worldwide and the prevalence of delta mutants and Omicron. Due to decreased vaccine protective efficacy in humans over time, new cases still emerge in an endless stream. In the interim analysis data of Phase III clinical trial released by Johnson & Johnson Ad26 adenovirus vector COVID-19 vaccine on January 29, 2021, 468 of the 43,783 subjects were infected with COVID-19. This unique pattern raises an important question, why does infection still occur during the period of antibody protection after vaccination? a) It may be related to antibody production time and titer. b) immunosuppressive parasite infection could be an important factor that has been ignored and never been investigated as a potential cause of vaccine failure.
Nowadays, with the development of the economy, people are petting cats for emotional support (2). Feline is the definitive host of Toxoplasma gondii (T. gondii), where oocysts, the infective stage, can be discharged, causing environmental contamination and widespread infection. According to statistics, the seroprevalence of T. gondii varies from less than 10-60% in the world’s nations (3). T. gondii, as a zoonotic parasitic disease, acute or chronic infections, can cause systemic or local immunosuppression of the host. Studies have shown that 65% of patients with HIV die from the re-activation of T. gondii infection in the first year after diagnosis (4). It is well documented that T. gondii has developed mechanisms to evade the attack by the host immune system (5, 6). Serological testing for T. gondii is not compulsory, and there is no T. gondii vaccine. In the case of such a high seropositivity rate, the antibody titers of the people injected with COVID-19 vaccines may be affected by suppressive T. gondii infection. We hypothesize that this could be one of the important neglected reasons for the low vaccine protection rate and should raise the attention of the Centers for Disease Control and Prevention worldwide.
Even though we are unsure whether T. gondii infection is connected to COVID-19 vaccination failure, we should test for immunosuppressive pathogens like T. gondii in vaccination failure patients to confirm the connection between vaccination failure and immunosuppression and to increase the efficacy and protection rate of COVID-19 vaccines.
Author contributions
HY, YS, X-XZ, and JZ are responsible for writing the draft. JZ is responsible for revising the manuscript. Z-GY is responsible for the conception and polishing the MS. All authors contributed to the article and approved the submitted version.
Funding
This work was supported by the National Natural Science Foundation of China (31972707) and Guangdong Provincial Forestry Department's Provincial Financial Special Fund for Ecological Forestry Construction-Wildlife Conservation.
Acknowledgments
We sincerely thank the support of Yasser Mahmmod for his overview and precious suggestion on the article.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
ReferencesNational Health Commission of the People’s Republic of China. Up to 24:00 on 24th August, the latest situation of new coronavirus vaccination. Availble at: https://www.nhc.gov.cn/jkj/s7915/202208/6c767517c5c446dc9fe733956bfb7fdb.shtmlKochanowskyJAKoshyAA. Toxoplasma gondii. Curr Biol (2018) 28:R770–1. doi: 10.1016/j.cub.2018.05.035PappasGRoussosNFalagasME. Toxoplasmosis snapshots: global status of Toxoplasma gondii seroprevalence and implications for pregnancy and congenital toxoplasmosis. Int J Parasitol (2009) 39:1385–94. doi: 10.1016/j.ijpara.2009.04.003MayorAMSantosDFDworkinMSRios-OlivaresEHunterRF. Toxoplasmic encephalitis in an AIDS cohort at Puerto Rico before and after highly active antiretroviral therapy (HAART). Am J Trop Med (2011) 84:838–41. doi: 10.4269/ajtmh.2011.10-0718MelchorSJEwaldSE. Disease tolerance in Toxoplasma infection. Front Cell Infect Microbiol (2019) 9:185. doi: 10.3389/fcimb.2019.00185ZhaoXYEwaldSE. The molecular biology and immune control of chronic Toxoplasma gondii infection. J Clin Invest (2020) 130:3370–80. doi: 10.1172/JCI136226